Asset profile
DehydraTECH-CBD/semaglutide
Small molecule
Evidence outlook · lead readout
NCT06648031 · Type2diabetes
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06648031: Participants were randomized to parallel arms including an active comparator, but the trial was not blinded, the primary endpoint was safety rather than a glycemic or weight outcome, and no results have been posted yet, so the eventual finding remains unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.